skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

From the beginning of 2021, companies wanting an orphan drug designation in Great Britain will need to apply for it at the same time as they file the marketing authorization application (MAA), using a new application form. There will be "no pre-marketing authorization orphan designation” for Great Britain, says new guidance on post-Brexit medicines regulation.

Incentives for orphan drug development will be provided in the form of market exclusivity and “full or partial refunds for marketing authorization fees,” and waivers from scientific advice fees will also be available for UK-based small and medium-sized companies. 

The guidance, published by the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 1 October and taking effect on 1 January, is needed because from next year the MHRA will take over responsibility for products currently governed by EU regulations. It is an update of the original document issued by the MHRA in 2019 in advance of a possible “no-deal Brexit,” but it will apply only to Great Britain (England, Scotland and Wales).

This is because under the Northern Ireland Protocol, which is part of the Brexit Withdrawal Agreement, EU rules on orphan designation (and other EU medicines regulations) will continue to apply in Northern Ireland after the end of the transition period on 31 December.

Most of the GB guidance is modeled on current EU rules, although it diverges in some respects, notably in the timing of the submission for orphan drug designation, which in the EU can be done at any time during the development process but in any case before the MAA is filed.


To qualify for orphan designation, a medicine will have to meet a number of criteria:

  • It must be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating.

  • The prevalence of the condition in Great Britain must be no more than 5 people in 10,000, or it must be “unlikely that marketing of the medicine would generate sufficient returns to justify the investment needed for its development.”

  • There must be no other satisfactory method of diagnosis, prevention or treatment of the condition in GB, “or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.” Satisfactory methods may include authorized medicines, medical devices or other methods of diagnosis, prevention or treatment used in GB.

Filing An Application

Sponsors seeking a designation – which will not attract any additional fee – must use a new “Great Britain Orphan Drug Designation Application Form” with their MAA in Module 1.2 of the electronic Common Technical Document, “specifically indicating in the cover letter their intention to seek an orphan designation.”

Applications will be examined by the MHRA’s Commission on Human Medicines (CHM) in parallel with the assessment of the MAA, and the decision on orphan status will be made at the same time as the marketing authorization decision. “Any questions concerning the fulfilment of the orphan designation criteria will be raised with the company during the evaluation of the MAA.”

The MHRA also provides for an appeals procedure before the CHM if the agency decides that the orphan designation criteria are not met – the applicant should inform the MHRA of its intention to appeal “as soon as possible.”

Market Exclusivity Incentive

The 10-year market exclusivity incentive that comes with a successful GB orphan designation is in line with that offered by the EU legislation, but with one difference: the guidance states that the GB exclusivity will be “up to 10 years.” This is because the exclusivity period will begin from the date of first approval of the product “in GB or EU/EEA.” This would mean that if the EU marketing authorization (MA) for the product were granted before the GB one, the exclusivity period for the latter would be reduced accordingly.

The government does not explain why it has done this, but a similar provision was included in draft no-deal contingency legislation published in 2019, linking both data and market exclusivity to the first marketing authorization in either the UK or the EU. An impact assessment accompanying the legislation said the provision would "encourage companies to submit applications for innovative products as soon as possible."

The UK Bioindustry Association said at the time that linking the start of exclusivity periods to the EU "does not make sense." It said it had been told by its member companies that the provision would not have the intended outcome but would instead send "a strong negative signal to global boardrooms about the UK as a location for investment." (Also see "UK Industry Skeptical Of Govt’s No-Deal Brexit Filing Expectations" - Pink Sheet, 18 Feb, 2019.)

Pediatric Extensions, New Indications

In line with EU regulations, the GB exclusivity period can be extended by two years if the results of studies conducted according to a pediatric investigation plan (PIP) are included in the product information.

Where a company applies for new or extended therapeutic indications for an orphan drug, the orphan criteria will be assessed in parallel with the evaluation of the new indication. A fresh exclusivity period will be awarded only if the indication falls within the definition of a new orphan condition.

All products that go on to obtain an orphan MA will be listed on the new “GB Orphan Register”.

As for "grandfathered" products, the guidance says that market exclusivity periods for orphans that were authorized under the EU's centralized system and whose MAs are converted to UK marketing authorizations as of 1 January 2021 “will continue to apply.”

The EU is considering whether to update its legislation on orphan drugs after a report published this summer said that the available tools had not done enough to direct orphan development to areas of greatest medical need and suggested that the exclusivity period might need to be shortened because in some rare disease areas the market had started to “look more similar to ‘standard’ medicines.” (Also see "Long-Awaited EU Review Questions 10-Year Orphan Exclusivity" - Pink Sheet, 12 Aug, 2020.)


Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: